pm mfvt1
    • Main page
      • About journal
      • Articles. Working with contents
      • Editor-in-chief
      • Editorial Council
      • Editorial Board


      • For authors
      • Standards for formatting information
      • Reviewing
      • Politics editorial board
      • Ethics of journal publications


      • For advertisers
      • Subscription
      • About the Publishing House
      • Contact us
  • Alport syndrome and the polypharmacy problem in the practice of ENT specialists

    Редактор | 2020, Clinical case, Practical medicine part 18 №6. 2020 | 30 ноября, 2020

    R.N. MAMLEEV1, 2, A.V. SINCHUGOV2, R.M. ASADULLINA1

    1Kazan State Medical University, Kazan

    2Children’s Republican Clinical Hospital, Ministry of Health of Republic of Tatarstan, Kazan

    Contact details:

    Mamleev R.N. — PhD (medicine), Associate Professor of Department of Hospital Pediatrics

    Address: 49 Butlerov St., Russian Federation, Kazan, 420012, tel.: +7-917-921-12-70, e-mail: r.mamleev@mail.ru

     Genetically determined diseases, Alport syndrome in particular, are traditionally the object of polypharmacy. The addition of intercurrent infection aggravates this situation, since it requires comedication directed at the focus of infection. Multiple drug interactions, which lead to a weakening of the therapeutic effect of some drugs and increase the toxic potential of others, require attention from all participants of the therapeutic process.

    Key words: Alport syndrome, acute otitis externa, polypharmacy.

     REFERENCES

    1. Savige J., Ariani F., Mari F. et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. PediatrNephrol, 2019, vol. 34 (7), pp. 1175–1189. DOI:10.1007/s00467-018-3985-4
    2. Wang F., Zhao D., Ding J., Li X. The First COL4A5 Exon 41A Glycine Substitution in a Family With Alport Syndrome. Front Pediatr, 2020, vol. 8, p. 153. Published 2020 Apr 9. DOI:10.3389/fped.2020.00153
    3. Alport A.C. Hereditary familial congenital haemorrhagic nephritis. Br. Med. J., 1927, vol. 1, pp. 504–506.
    4. Nagel M., Nagorka S., Gross O. Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome. Hum. Mutat., 20085, vol. 26, p. 60.
    5. Hertz J.M., Thomassen M., Storey H., Flinter F. Clinical utility gene card for: Alport syndrome. Eur J Hum Genet, 2012, vol. 20 (6). DOI:10.1038/ejhg.2011.237
    6. Gao E., Yang X., Si N., Liu K., Wang J.Q., Liu Z. A Novel COL4A5 Splicing Mutation Causes Skipping of Exon 14 in a Chinese Family with Alport Syndrome. Kidney Dis (Basel)., 2020, vol. 6 (1), pp. 43–49. DOI:10.1159/000502798
    7. Funk S.D., Bayer R.H., Miner J.H. Endothelial cell-specific collagen type IV-α3 expression does not rescue Alport syndrome in Col4a3-/- mice. Am J Physiol Renal Physiol., 2019, vol. 316 (5), pp. F830–F837. DOI:10.1152/ajprenal.00556.2018
    8. Shagam L.I., Shentseva D.V. Molecular genetic basis of the pathogenesis of Alport syndrome. Rossiyskiy vestnik perinatologii i pediatrii, 2013, no. 6, pp. 25–27.
    9. Rintelmann W. Auditory manifestations of Alport’s disease syndrome. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol, 1976, vol. 82 (3 Pt 1), pp. 375–387.
    10. Gleeson M.J. Alport’s syndrome: audiological manifestations and implications. J Laryngol Otol, 1984, no. 98449, p. 465.
    11. Barilyak V.V., Mileshina N.A., Moskalets Yu.A., Generalova G.A., Markova M.V., Tsygankova E.R. Changes in auditory function in children with chronic kidney disease. Vestnik otorinolaringologii, 2018, vol. 83, no. 4, pp. 56–59 (in Russ.). DOI: org/10/17116/otorino201883456
    12. Weber P.C., Cunningham C.D. 3rd, Schulte B.A. Potassium recycling pathways in the human cochlea. Laryngoscope, 2001, vol. 111 (7), pp. 1156–1165. DOI: 10.1097/00005537-200107000-00006
    13. Harvey S.J., Mount R., Sado Y. et al. The inner ear of dogs with X-linked nephritis provides clues to the pathogenesis of hearing loss in X-linked Alport syndrome. Am J Pathol., 2001, vol. 159 (3), pp. 1097–1104. DOI: 10.1016/S0002-9440(10)61785-3
    14. Jais J.P., Knebelmann B., Giatras I. et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a «European Community Alport Syndrome Concerted Action» study. J Am Soc Nephrol, 2003, vol. 4 (10), pp. 2603–2610. DOI: 10.1097/01.asn.0000090034.71205.74
    15. Cadogan C., Ryan C., Gormley G., Passmore P., Francis J., Kerse N. et al. Dispensing appropriate polypharmacy to older people in primary care: a qualitative, theory-based study of community pharmacists’ perceptions and experiences. Int J Pharm Pract., 2015, vol. 23, p. 32. DOI: 10.1111/ijpp.12182
    16. Dlin V.V., Ignatov M.S., Kon’kova N.E. Clinical guidelines for the diagnosis and treatment of Alport syndrome in children. Nefrologiya, 2015, vol. 19, no. 3, pp. 86–89 (in Russ.). UDK: 616.61-053.32-056.7-07.08

    Метки: 2020, A.V. SINCHUGOV, acute otitis externa, Alport syndrome, polypharmacy, Practical medicine part 18 №6. 2020, R.M. ASADULLINA, R.N. Mamleev

    ‹ Assessment of the opinion of medical personnel about vaccination Critical heart disease (atresia of the pulmonary artery with an intact interventricular septum) in pediatric practice ›
    • rus Версия на русском языке


      usa English version site


      Find loupe

      

    • PARTNERS

      пов  logonew
    «Для
    Practical medicine. Scientific and practical reviewed medical journal
    All rights reserved ©